Sign in

PURE on OTC

PURE BIOSCIENCE, INC.

PURE BIOSCIENCE, INC. is an American miscellaneous chemical products company, incorporated in Delaware.1 It is headquartered in El Cajon, California.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$2.2MRevenue, fiscal 20252
-$2.4MNet income, fiscal 20252

Compare with ASP Isotopes Inc., FLEXIBLE SOLUTIONS INTERNATIONAL INC or Arq, Inc., or pick any stock.

  • TickerPURE on OTC1
  • IndustryMiscellaneous Chemical Products1
  • HeadquartersEl Cajon, California1
  • Incorporated inDE3
  • Business address771 Jamacha Road #512, El Cajon, Ca 920193
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

Savings: Utilizing distributors can reduce overhead costs associated with logistics, warehousing, and inventory management.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

59.2%Gross margin2
-103.2%Operating margin2
-108.9%Net margin2
12.2%Revenue growth, 20252

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue20¢$899.0K
  • Research and development7¢$316.0K
  • Selling, general and admin73¢$3.3M

Out of $2.2M in revenue.2 The company lost money this year.

Financial statements

Revenue56789102$2.2M in 2025+24% since 2018
0$2.0M$4.0M$6.0M$8.0M2018: $1.8M$1.8M20182019: $1.9M$1.9M2019+8%2020: $6.9M$6.9M2020+262%2021: $3.9M$3.9M2021−43%2022: $1.9M$1.9M2022−53%2023: $1.9M$1.9M2023+1%2024: $2.0M$2.0M2024+5%2025: $2.2M$2.2M2025+12%
Gross profit6789102$1.3M in 2025+10% since 2019
0$2.0M$4.0M$6.0M2019: $1.2M$1.2M20192020: $4.0M$4.0M2020+240%2021: $2.1M$2.1M2021−48%2022: $1.0M$1.0M2022−52%2023: $971.0K$971.0K2023−3%2024: $1.2M$1.2M2024+19%2025: $1.3M$1.3M2025+13%
Operating income56789102-$2.3M in 2025−68% since 2018
-$8.0M-$6.0M-$4.0M-$2.0M0$2.0M2018: -$7.0M-$7.0M20182019: -$5.6M-$5.6M2019−21%2020: $4.0K$4.0K20202021: -$2.3M-$2.3M20212022: -$3.7M-$3.7M2022+61%2023: -$3.9M-$3.9M2023+6%2024: -$3.2M-$3.2M2024−19%2025: -$2.3M-$2.3M2025−29%
Net income56789102-$2.4M in 2025−68% since 2018
-$8.0M-$6.0M-$4.0M-$2.0M0$2.0M2018: -$7.4M-$7.4M20182019: -$6.6M-$6.6M2019−12%2020: $4.0K$4.0K20202021: -$2.3M-$2.3M20212022: -$3.5M-$3.5M2022+51%2023: -$4.0M-$4.0M2023+13%2024: -$3.4M-$3.4M2024−15%2025: -$2.4M-$2.4M2025−28%
Fiscal year20182019202020212022202320242025
Revenue$1.8M5$1.9M6$6.9M7$3.9M8$1.9M9$1.9M10$2.0M2$2.2M2
Cost of revenue$763.0K5$728.0K6$2.9M7$1.9M8$853.0K9$906.0K10$811.0K2$899.0K2
Gross profit$1.2M6$4.0M7$2.1M8$1.0M9$971.0K10$1.2M2$1.3M2
Research and development$459.0K5$354.0K6$322.0K7$339.0K8$319.0K9$297.0K10$302.0K2$316.0K2
Selling, general and admin$5.2M5$6.4M6$3.7M7$4.0M8$4.1M9$4.3M10$4.0M2$3.3M2
Operating expenses$4.7M9$4.9M10$4.3M2$3.6M2
Operating income-$7.0M5-$5.6M6$4.0K7-$2.3M8-$3.7M9-$3.9M10-$3.2M2-$2.3M2
Interest$8.0K5$6.0K6$5.0K7$4.0K8$6.0K9$14.0K9
Income tax$1.6K5$1.6K6$1.6K7$1.6K8$1.6K9$010$02$02
Net income-$7.4M5-$6.6M6$4.0K7-$2.3M8-$3.5M9-$4.0M10-$3.4M2-$2.4M2
Earnings per share-$0.096$0.007-$0.038-$0.049-$0.0410-$0.032-$0.022
Earnings per share (diluted)-$0.096$0.007-$0.037-$0.049-$0.0410-$0.032-$0.022
Shares (weighted, basic)88.8M shares9111.4M shares10111.9M shares2111.9M shares2
Shares (weighted, diluted)88.8M shares9111.4M shares10111.9M shares2111.9M shares2

Compare PURE BIOSCIENCE, INC. with another company

What it owns

What PURE BIOSCIENCE, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.6M10 Jul 31, 2024$1.6M10 Jul 31, 20230%
Accumulated depreciation$1.6M2 Jul 31, 2025$1.6M2 Jul 31, 2024+0.1%
Property and equipment, net$11.0K2 Jul 31, 2025$13.0K2 Jul 31, 2024−15.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$334.0K2 Jul 31, 2025$349.0K2 Jul 31, 2024−4.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$141.0K2 Jul 31, 2025$56.0K2 Jul 31, 2024+151.8%
Raw materials$14.0K2 Jul 31, 2025$4.0K2 Jul 31, 2024+250.0%
Finished goods$127.0K2 Jul 31, 2025$52.0K2 Jul 31, 2024+144.2%

Properties, in its own words

Our mailing address is 771 Jamacha Road., #512, El Cajon, California 92019. Our executive officers and employees work remotely in a “virtual office” setting without lease obligations.

Item 2 of the 10-K filed Oct 29, 2025.4

Leadership

Who has led PURE BIOSCIENCE, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael L. Krall2006–2013
  2. Henry R. Lambert2013–2018
  3. Robert F. Bartlett2023–now

Chair

  1. David J. Pfanzelter2017–2018

President

  1. Michael L. Krall2006–2007
  2. Robert F. Bartlett2024–2025
  3. Jeffrey Scott Kitchell2025–now

Chief financial officer

  1. Andrew J. Buckland2006–2010
  2. Craig A. Johnson2011
  3. Peter C. Wulff2012–2013

Chief operating officer

  1. Peter C. Wulff2013
  2. Thomas Richard Myers2018–2023
2010201520202025
Board members and other officers (27)

Former names

  • PURE BIOSCIENCEOct 29, 2003 to Mar 17, 20113
  • INNOVATIVE MEDICAL SERVICESJul 5, 1996 to Sep 2, 20033

Timeline

  1. Jun 15, 20268-K Results of operations50
  2. May 5, 20268-K Entered a material agreement; Unregistered sale of shares51
  3. Mar 17, 20268-K Results of operations52
  4. Feb 20, 20268-K Shareholder vote53
  5. Dec 15, 20258-K Results of operations54
  6. Nov 19, 20258-K Executive or director change55
  7. Oct 29, 20258-K Results of operations56
  8. Jun 16, 20258-K Results of operations57
  9. Mar 17, 20258-K Results of operations58
  10. Jan 28, 20258-K Shareholder vote59
  11. Dec 16, 20248-K Results of operations60
  12. Oct 29, 20248-K Results of operations61
  13. Mar 22, 2023New chief executive Robert F. Bartlett becomes CEO15
  14. Sep 25, 2013New chief executive Henry R. Lambert becomes CEO16
  15. Apr 14, 2006New chief executive Michael L. Krall becomes CEO17

Calendar

When it reported results

  1. Jun 15, 2026Reported quarterly or annual results50
  2. Mar 17, 2026Reported quarterly or annual results52
  3. Dec 15, 2025Reported quarterly or annual results54
  4. Oct 29, 2025Reported quarterly or annual results56
  5. Jun 16, 2025Reported quarterly or annual results57
  6. Mar 17, 2025Reported quarterly or annual results58
  7. Dec 16, 2024Reported quarterly or annual results60
  8. Oct 29, 2024Reported quarterly or annual results61

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

95 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 34 major events, 32 insider forms, 9 other. The latest 20:

  1. Jun 15, 202610-Q EDGAR
  2. Jun 15, 20268-K EDGAR
  3. May 5, 20268-K EDGAR
  4. Mar 17, 202610-Q EDGAR
  5. Mar 17, 20268-K EDGAR
  6. Feb 20, 20268-K EDGAR
  7. Dec 30, 2025DEF 14A EDGAR
  8. Dec 18, 2025PRE 14A EDGAR
  9. Dec 15, 202510-Q EDGAR
  10. Dec 15, 20258-K EDGAR
  11. Nov 28, 20253 EDGAR
  12. Nov 19, 20258-K EDGAR
  13. Oct 29, 202510-K EDGAR
  14. Oct 29, 20258-K EDGAR
  15. Jun 16, 202510-Q EDGAR
  16. Jun 16, 20258-K EDGAR
  17. Mar 17, 202510-Q EDGAR
  18. Mar 17, 20258-K EDGAR
  19. Jan 28, 20258-K EDGAR
  20. Dec 16, 202410-Q EDGAR

The 95 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 22, 2023BARTLETT ROBERT FCEO and PresidentBuy50,000$0.16$8.0KForm 4
Mar 21, 2023Blotner BernardDirectorBuy10,000$0.13$1.3KForm 4
Dec 15, 2022Lee Tom YDirectorBuy50,000$0.13$6.5KForm 4
Mar 21, 2022Lee Tom YDirectorBuy185,000$0.20$37.0KForm 4
Mar 17, 2022Lee Tom YDirectorBuy13,250$0.18$2.4KForm 4
Mar 16, 2022Lee Tom YDirectorBuy21,227$0.18$3.8KForm 4

From Forms 4 filed with the SEC.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Tom Myers$188.0K$197.4K62
2025Robert Bartlett$151.9K$191.3K62
2025Mark Elliott50$169.2K$178.6K62
2024Chief Executive Officer$200.0K$215.0K62
2024Executive VicePresident of Technology & Development$200.0K$215.0K62
2024Vice President Finance$180.0K$195.0K62

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$238.8K 2021–2021
Money received by yearMoney received by year, 2021–2021: $238.8K in all. PPP loans $238.8K.$0$100K$200K$300K2021 · PPP loans: $238.8K2021
Figures by year
YearPPP loansTotal
2021$238.8K$238.8K

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA63. Matched to this company by name and state.

  1. Apr 11, 2021$238.8K PPP loan (first draw) from Zions Bank, A Division of63To PURE BIOSCIENCE INC, Rancho Cucamonga CA; $240.4K forgiven Dec 8, 2021

SEC filer profile

How PURE BIOSCIENCE, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPURE BIOSCIENCE, INC.1
  • CIK0001006028
  • Employer ID (EIN)33-05302894
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsJuly 311
  • Industry code (SIC)2890 Miscellaneous Chemical Products1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address771 Jamacha Road #512, El Cajon, CA 920191
  • Phone619-596-86001
  • Shares outstanding130,017,569 as of Jun 15, 202613
  • Public float$4.7M as of Jan 31, 20254
  • AuditorWeinberg & Company, P.A., Los Angeles, California PCAOB ID 572; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceMay 24, 19961
  • Filings997 in all: 4 (330), 8-K (195), 10-Q (57), 10QSB (33), 3 (30), DEF 14A (25), 424B3 (24), 4/A (20)1
    All 56 form types

    10QSB/A (19), 10-K (18), UPLOAD (18), S-8 (17), S-3/A (16), D (15), EFFECT (15), 10KSB/A (14), CORRESP (14), POS AM (10), PRE 14A (10), S-3 (10), 10KSB (8), 8-K/A (7), SB-2/A (7), 424B5 (6), 424B1 (5), DEFA14A (5), PRER14A (5), S-1 (5), 10KSB40 (4), 5 (4), S-1/A (4), DFAN14A (3), PRRN14A (3), REGDEX (3), RW (3), S-8 POS (3), SC 13D (3), SC 13G (3), SC TO-I/A (3), 8-A12B (2), 8-A12B/A (2), DEFR14A (2), PREC14A (2), SB-2 (2), SC 13D/A (2), 10-K/A (1), 10-Q/A (1), 10KSB40/A (1), 15-12G (1), 25-NSE (1), 8A12BT/A (1), CERTNAS (1), CT ORDER (1), FWP (1), S-3MEF (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Oct 29, 2025
    Quarterly report (10-Q) Jun 15, 2026
    Proxy statement (DEF 14A) Dec 30, 2025
    Latest 8-K (8-K) Jun 15, 2026

Risk factors and legal proceedings

The risks PURE BIOSCIENCE, INC. names in Item 1A of its 10-K filed Oct 29, 2025: 39 risks under these headings, as written.4

  • Risks Related to Our Business and Industry
  • As a result of our historical lack of financial liquidity, we do not currently have sufficient working capital to fund our planned operations and may not be able to continue as a going concern.
  • We have limited capital and will need to raise additional capital in the future.
  • We have a history of losses, and we may not achieve or maintain profitability.
  • Raising additional funds by issuing securities or through collaboration and licensing arrangements may cause dilution to existing stockholders, restrict our operations or require us to relinquish proprietary rights.
  • We need to continue to increase customer awareness and adoption of our food safety product offerings, PURE Hard Surface and PURE Control.
  • We may not be able to correctly estimate our future revenues and operating expenses, which could lead to cash shortfalls, and require us to secure additional financing sooner than planned.
  • Our quarterly operating results may vary, which could negatively affect the market price of our common stock.
  • A loss of one or more of our key customers could adversely affect our business.
  • We are dependent on our core SDC technology and if our efforts to achieve or maintain market acceptance of our core SDC technology are not successful, we are unlikely to continue to maintain profitability.
  • We are subject to intense competition in the food safety market.
  • We have limited sales, marketing and product distribution experience.
The other 28 risks
  • We are dependent on a third-party, over whom we have limited control, to manufacture our SDC-based products.
  • We rely on third parties to develop SDC-based products, and they may not do so successfully or diligently.
  • Pricing and supply issues may have a material impact on our margins and our ability to supply our customers.
  • If we are not able to manage any growth we achieve effectively, our business and operating results will be harmed.
  • If we suffer negative publicity concerning the safety or efficacy of our products, our sales may be harmed.
  • We may become subject to product liability claims.
  • We depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder our ability to move forward with our business plan.
  • Because competition for highly qualified sales and marketing and management personnel is intense, we may not be able to attract and retain the employees we need to support our potential growth.
  • We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.
  • We may invest or spend our cash in ways with which you may not agree or in ways which may not yield a significant return.
  • We may not be able to utilize all, or any, of our tax net operating loss carry-forwards and our future after-tax earnings, if any, could be reduced.
  • Risks Related to the Regulation of our Products
  • If we are unable to obtain the required regulatory approvals from the FDA and USDA, or if such efforts are delayed, our ability to commercialize PURE Control as a direct food contact processing aid will be harmed and our business and operating results will suffer.
  • The industries in which we operate are heavily regulated.
  • We are subject to substantial regulation related to quality standards applicable to our manufacturing and quality processes, and our or our partners, including our third-party manufacturers, failure to comply with applicable quality standards could affect our ability to commercialize SDC products.
  • Litigation or the actions of regulatory authorities may harm our business or otherwise distract our management.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain, maintain or defend the patent and other intellectual property rights relating to our technology, we or our collaborators and distributors may not be able to develop and market proprietary products based on our technology, which would have a material adverse impact on our results of operations.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use, our technology.
  • Third parties may claim that we infringe their proprietary rights and may prevent us from manufacturing and selling some of our products.
  • Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete.
  • We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • Risks Related to our Common Stock
  • The price of our common stock has been and may continue to be volatile.
  • Potential sales or issuances of our common stock to raise capital, or the perception that such sales could occur, could cause dilution to our current stockholders and the price of our common stock to fall.
  • Our common stock is deemed to be “penny stock,” which may make it more difficult for investors to sell their shares due to suitability requirements.
  • We have never paid dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable future.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control and could also limit the market price of our stock.
  • General Risk Factors
  • Compliance with the reporting requirements of federal securities laws can be expensive.
  • If we fail to maintain an effective system of internal controls, we may not be able to accurately determine our financial results or prevent fraud. As a result, the Company’s stockholders could lose confidence in our financial results, which could harm our business and the value of the Company’s common shares.
  • We are subject to tax audits by various tax authorities in multiple jurisdictions.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not currently aware of any such legal proceedings or claims to which we or our wholly owned subsidiary is a party or of which any of our property is subject that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63